Induction of CYP3A4 by 1 alpha,25-dihydroxyvitamin D3 is human cell line-specific and is unlikely to involve pregnane X receptor.

Under certain culture conditions, exposure of the human colon adenocarcinoma cell line Caco-2 to 1,25-(OH)(2)-D(3) induces expression of CYP3A4 to levels comparable to that in human small intestinal epithelium. To determine whether 1,25-(OH)(2)-D(3) could be used to restore CYP3A expression in other culture models, we examined several cell lines derived from malignancies of human tissues known to express CYP3A enzymes: Hep G2 (liver), LS180 (colon), HPAC (pancreas), Hs746T (stomach). Primary cultures of human hepatocytes from two donors were also examined. 1,25-(OH)(2)-D(3) increased CYP3A catalytic activity in LS180 (15-fold), HPAC (6-fold), and hepatocytes (2- to 3-fold); this was accompanied by induction of CYP3A4 mRNA and CYP3A immunoreactive protein. However, 1,25-(OH)(2)-D(3) had no effect on CYP3A expression in Hs746T or Hep G2. Known ligands for pregnane X receptor (PXR) (rifampin, dexamethasone, and dexamethasone t-butyl acetate) markedly induced CYP3A4 expression in human hepatocytes. In contrast, these ligands had little or no effect on CYP3A4 expression in Caco-2 cells, even at concentrations 1 to 2 orders of magnitude greater than effective concentrations of 1,25-(OH)(2)-D(3) or two other vitamin D receptor (VDR) ligands (25-OH-D(3) and 1-OH-D(3)). The retinoic acid receptor ligand all-trans-retinoic acid augmented the 1,25-(OH)(2)-D(3)-mediated induction of CYP3A4 catalytic activity up to 2-fold in Caco-2 cells, while having no demonstrable effect on levels of CYP3A4 mRNA or protein. The retinoid X receptor ligand 9-cis-retinoic acid appeared to slightly reduce CYP3A4 catalytic activity. We conclude that 1,25-(OH)(2)-D(3) can be used to increase CYP3A4 expression in some, but not all, human cell lines derived from tissues known to express CYP3A enzymes. The mechanisms involved in this induction are unlikely to involve PXR and may involve VDR.

[1]  C. Carlberg,et al.  All natural DR3-type vitamin D response elements show a similar functionality in vitro. , 2000, The Biochemical journal.

[2]  J. Azuma,et al.  Quantitative analysis of constitutive and inducible CYPs mRNA expression in the HepG2 cell line using reverse transcription-competitive PCR. , 2000, Biochemical and biophysical research communications.

[3]  B. Goodwin,et al.  The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. , 1999, Molecular pharmacology.

[4]  P. Watkins,et al.  First-pass midazolam metabolism catalyzed by 1alpha,25-dihydroxy vitamin D3-modified Caco-2 cell monolayers. , 1999, The Journal of pharmacology and experimental therapeutics.

[5]  S. Wrighton,et al.  Midazolam metabolism by modified Caco-2 monolayers: effects of extracellular protein binding. , 1999, The Journal of pharmacology and experimental therapeutics.

[6]  R. Fontana,et al.  Molecular and physical mechanisms of first-pass extraction. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[7]  W. Sabbagh,et al.  SXR, a novel steroid and xenobiotic-sensing nuclear receptor. , 1998, Genes & development.

[8]  R Ohlsson,et al.  Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[9]  J. Lehmann,et al.  The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. , 1998, The Journal of clinical investigation.

[10]  P. Watkins,et al.  Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3. , 1997, Molecular pharmacology.

[11]  D. Shen,et al.  First‐pass metabolism of midazolam by the human intestine , 1996, Clinical pharmacology and therapeutics.

[12]  R. Tukey,et al.  Trans-species gene transfer for analysis of glucocorticoid-inducible transcriptional activation of transiently expressed human CYP3A4 and rabbit CYP3A6 in primary cultures of adult rat and rabbit hepatocytes. , 1996, Molecular pharmacology.

[13]  M. Langman,et al.  Antiproliferative responses to two human colon cancer cell lines to vitamin D3 are differently modified by 9-cis-retinoic acid. , 1996, Cancer research.

[14]  E. Schuetz,et al.  Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. , 1996, Molecular pharmacology.

[15]  C. Ackerley,et al.  The structure and organization of the bile canalicular cytoskeleton with special reference to actin and actin‐binding proteins , 1995, Hepatology.

[16]  J. Kolars,et al.  Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[17]  J. Kolars,et al.  CYP3A gene expression in human gut epithelium. , 1994, Pharmacogenetics.

[18]  J. Grande,et al.  Immunohistochemical localization of the 1,25(OH)2D3 receptor and calbindin D28k in human and rat pancreas. , 1994, The American journal of physiology.

[19]  R. Fisher,et al.  Regulation of human liver cytochromes P‐450 in family 3A in primary and continuous culture of human hepatocytes , 1993, Hepatology.

[20]  J. Kolars,et al.  Cultured adult rat jejunal explants as a model for studying regulation of CYP3A. , 1993, Biochemical Pharmacology.

[21]  R. Sormunen,et al.  Bile canaliculus formation in cultured HEPG2 cells. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[22]  J. Kolars,et al.  Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. , 1992, The Journal of clinical investigation.

[23]  A. Giuliano,et al.  Characterization of the vitamin D receptor from the Caco-2 human colon carcinoma cell line: effect of cellular differentiation. , 1991, Archives of biochemistry and biophysics.

[24]  A B West,et al.  Localization of villin, a cytoskeletal protein specific to microvilli, in human ileum and colon and in colonic neoplasms. , 1988, Gastroenterology.

[25]  M. Traber,et al.  Polarized secretion of newly synthesized lipoproteins by the Caco-2 human intestinal cell line. , 1987, Journal of lipid research.

[26]  P. Watkins,et al.  Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. , 1987, The Journal of clinical investigation.

[27]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[28]  J. Gielen,et al.  Monoclonal antibodies against human liver cytochrome P-450. , 1985, Biochemical pharmacology.

[29]  H. Bonkovsky,et al.  Cytochrome P450 of small intestinal epithelial cells , 1985 .

[30]  H. Bonkovsky,et al.  Cytochrome P450 of small intestinal epithelial cells. Immunochemical characterization of the increase in cytochrome P450 caused by phenobarbital. , 1985, Gastroenterology.

[31]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[32]  J. Hochman,et al.  Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4. , 2000, The Journal of pharmacology and experimental therapeutics.

[33]  J. Lehmann,et al.  The PPARs and PXRs: nuclear xenobiotic receptors that define novel hormone signaling pathways. , 1999, Recent progress in hormone research.

[34]  M. Haussler,et al.  The vitamin D hormone and its nuclear receptor: molecular actions and disease states. , 1997, The Journal of endocrinology.

[35]  J. Kolars,et al.  Erratum: Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: Lack of prediction by the erythromycin breath test (Drug Metabolism and Disposition (1994) 22 (947-955)) , 1995 .

[36]  Benveniste,et al.  Cytochrome P450 , 1993, Handbook of Experimental Pharmacology.

[37]  J. Bausch,et al.  Monoclonal antibodies. , 1990, Bioprocess technology.

[38]  T. Shimada,et al.  Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[39]  M. Haussler,et al.  Immunocytochemical detection of 1,25-dihydroxyvitamin D receptors in normal human tissues. , 1987, The Journal of clinical endocrinology and metabolism.